Amylyx targets LUCIDITY top line data next quarter while launching expanded access for up to 250 PBH patients
Source: SeekingAlpha
2026-05-07 17:03:58 ET
More on Amylyx Pharmaceuticals
- Amylyx Pharmaceuticals, Inc. (AMLX) Q1 2026 Earnings Call Transcript
- Amylyx: LUCIDITY Trial Sets Stage For Q3 Inflection Point
- Amylyx Pharmaceuticals, Inc. (AMLX) Q4 2025 Earnings Call Transcript
- Amylyx anticipates LUCIDITY trial results in Q3 2026 while advancing PBH market strategy
- Amylyx Pharmaceuticals Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Amylyx targets LUCIDITY top line data next quarter while launching expanded access for up to 250 PBH patients
Amylyx Pharmaceuticals Inc.
NASDAQ: AMLX
AMLX Trading
-2.25% G/L:
$13.31 Last:
622,419 Volume:
$14.25 Open:
AMLX Latest News
AMLX Stock Data
$1,635,213,382
76,324,600
0.74%
41
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
